You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series

Article info

Article menu

Download PDFPDF

XML
Case Report
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series

Authors

  1. ↵a Naqasha16{at}ecu.edu
  2. ↵b Danielle.File{at}unchealth.unc.edu
  3. ↵c Carolyn_Ziemer{at}med.unc.edu
  4. ↵d Young_Whang{at}med.unc.edu
  5. ↵e Paula.Landman{at}unchealth.unc.edu
  6. ↵f Paul_Googe{at}med.unc.edu
  7. ↵g frances_collichio{at}med.unc.edu
View Full Text

Citation

Naqash AR, File DM, Ziemer CM, et al
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series
Journal for ImmunoTherapy of Cancer 2019;7:4. doi: 10.1186/s40425-018-0475-y

Publication history

  • Received October 28, 2018
  • Accepted December 6, 2018
  • First published January 8, 2019.
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.